Search results
Showing 1 to 15 of 17 results for itp
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.
A timeline showing where in the NICE evaluation process companies will be charged.
Charging procedure for NICE technology appraisal and highly specialised technologies evaluations
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549
In development Reference number: GID-TA11722 Expected publication date: 20 May 2027
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
In development Reference number: GID-HST10063 Expected publication date: TBC
In development Reference number: GID-TA11956 Expected publication date: 28 January 2027
analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes...
Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.
Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)
Evidence-based recommendations on routine anti-D prophylaxis for women who are rhesus D negative.
View recommendations for TA156Show all sections
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.